Abstract Asian and western countries differ in the prevalence, symptom manifestation, diagnostic procedures, patient recognition and treatments of major depressive disorder (MDD), according to a number of studies. Ethnic differences in pharmacological profiles are also important in the prescription of certain antipsychotic medications because they may impact treatment outcomes and adverse events. Differential pharmacokinetic and pharmacodynamic properties of antipsychotics may be practically useful in the control of specific depressive symptoms. Furthermore, patient compliance with prescribed medications has been found to be different across races and ethnicities. Therefore, this article explores practical clinical issues for the use of atypical antipsychotics in patients with MDD, focusing on ethno-cultural differences.
Substantial differences have been reported in the prevalence, symptom manifestation, developmental mechanisms, patients' recognition and treatment of major depressive disorder (MDD) across different ethnicities [1] . For instance, the prevalence of lifetime MDD in east Asia was less than 3 %, versus 16 % in the USA; however, according to a World Health Organization report, the suicide rate in Korea is the highest (31.2/100,000 population and one out of five in MDD patients) among developed countries, which is in contrast to the findings of other prevalence studies, suggesting hidden underlying mental health problems, including MDD [1, 2] . The remarkably low prevalence rates of depression in the Asian population may arise from study methodologies, cultural backgrounds in thinking about emotional distress and MDD symptoms, fear of being stigmatized by addressing mental disorders, or the protective effects of family and social support. According to a recent large epidemiological study in Korea, only 10 % of subjects with clinical depression were found to receive any form of treatment for depression, which is lower than in western countries [3] . Treatment compliance is also substantially different across races and ethnicity. Therefore, it is essential to screen patients properly for symptoms of MDD. Considering the very busy clinical practices in Asia due to problematical national insurance systems, the use of brief self-rating scales of MDD is recommended to evaluate the severity of depressive symptoms [4, 5] .
Interestingly, Asian and western countries have different profiles of depressive symptoms: Asian MDD patients present as more agitated, anxious and irritable, with lower positive affect and widespread somatic symptoms, while western patients show more affective symptoms than physical symptoms [4] . These differences in MDD symptom manifestation have been consistently reported in a number of studies [4] . These trends were strongly replicated in a recent Asian collaborative study investigating the frequency of somatic symptoms in six countries (frequency range of somatic symptoms 35.1-73.3 %) [6] .
Consideration of different pharmacodynamic profiles, including affinity on various neurotransmitters and monoamine receptors among each atypical antipsychotic (AA), should also be beneficial for controlling such florid symptoms of MDD when current antidepressants are not adequately effective, especially concerning patient clinical status [7] . According to a recent pooled analysis, quetiapine significantly reduced the symptoms of generalized anxiety disorder, with improvements beginning from week 1; quetiapine also has a favourable profile on sleep disturbance for MDD patients [8] . Quetiapine augmentation may be preferable for MDD patients who are agitated, anxious and with poor sleep quality. A low dose (2.5 mg/day) of aripiprazole augmentation with antidepressants was also effective, showing a significant improvement of somatic symptoms and psychomotor retardation in patients with MDD [9] .
Learning more about the differential experience and manifestation of MDD across ethnic and racial groups will help clinicians evaluate, diagnose and treat MDD more efficiently and effectively [4] . Ethno-cultural modifications in the evaluation and treatment of MDD should also be considered to reflect their cultural diversity maximally.
Clinical Points for the Use of Atypical Antipsychotics for Major Depressive Disorder Regarding Ethnic Differences
According to a recent meta-analysis [10] , adjunctive AAs were significantly more effective in terms of response and remission than placebo. However, rates of discontinuation due to adverse events (AEs) were as much as four times higher for AAs than for placebo. In addition, there were no differences in efficacy and discontinuation rates across AAs, but the profile of major AEs may be substantially different for different AAs. It is well known that compliance to antidepressant therapy is significantly reduced by AEs at an early treatment stage. It is well known that there are substantial pharmacokinetic variations in the metabolism of AAs between Asian and Caucasian populations [11, 12] . In particular, combinations of AAs and antidepressants may increase the risk of developing drug-drug interactions, which are associated with AEs [13] . The cytochrome P450 (CYP) 2D6 and genetic polymorphisms for this CYP isoenzyme system are quite different between Asian and western countries [13] . The overall lower CYP2D6 activity has been consistently observed in east Asians due to the higher variant allele CYP2D6*10 leading to alteration of the enzyme activity, resulting in a lower capacity to metabolize certain drugs that are substrates of CYP2D6, such as antidepressants and antipsychotics [14] [15] [16] . Therefore, as fluoxetine and paroxetine are both inhibitors of CYP2D6, they are likely to increase aripiprazole plasma levels. In addition, major enzyme activity depends on the medication dose (e.g. differential enzyme involvement in drug metabolism: CYP3A4 for a high dose of haloperidol and CYP2D6 for a lower dose). The CYP2C19 polymorphism has also to be considered because it is one of the most important polymorphisms in the Asian population. It may affect dosing of citalopram, escitalopram and also sertraline (CYP3A4). The lower activity is related to the presence of the CYP2C19*3 allele that is relatively common in Asian individuals, and which is scarce in other major ethnic groups [14] . The frequency of CYP2D6 variants based on ethnicity has been summarized in Table 1 [17]. How should clinicians adjust doses of AAs for Asian MDD patients? Although there is no clear evidence indicating a dose-response relationship in most antipsychotic augmentation studies, tolerability issues are proportionally increased with dose increment. However, MDD response rates were significantly higher with adjunctive quetiapine XR 300 mg/day (but not 150 mg/day) than with an antidepressant plus placebo in quetiapine XR augmentation studies among the US population [18] . The NNT to achieve an additional response over antidepressant plus placebo were 11-18 and eight to nine in quetiapine XR 150 mg/day and 300 mg/day, respectively [18] . This indicates that increasing the AA dose is still a viable option for inadequate responders at the initial dose. However, currently available data indicate that the minimally effective AA dose is likely to enhance the likelihood of good treatment outcomes in Asian patients. Most recent studies have suggested that the optimal starting and target daily doses of aripiprazole may be between 2-5 and 10-15 mg/day, which appear tolerable for most depressed patients [9, [19] [20] [21] [22] , in contrast to earlier findings [23] [24] [25] [26] [27] . The authors of the aripiprazole registration trials thought that the adjunct aripiprazole for patients with MDD would require a lower dose than they initially considered [26, 27] . Similarly, a recent controlled trial has found that a low dose of 2.5 mg/day of aripiprazole augmentation was efficacious and tolerable in Taiwanese patients with MDD [9] . In a recent Japanese study, the mean dose of aripiprazole with selective serotonin reuptake inhibitors was also less than 10 mg/day [21] . In fact, in the first study [24] of aripiprazole in Asian MDD patients (mean starting dose 5.5 mg/day and target dose 10 mg/day) that adopted a relatively high dosing strategy compared to recent trends conducted in the Asian population [9, 20, 21] , 23 % of subjects experienced extrapyramidal symptoms (EPSs) during the study, whereas no one had EPSs in the low-dose (fixed 2.5 mg/day) Taiwanese study [9] . Given these findings, the optimal dose of AAs for MDD in the Asian population seems to be substantially lower than for Caucasians; the clear establishment of appropriate starting, target and maintenance doses specifically for Asian patients is warranted.
A recent pooled analysis suggests that east Asian patients (e.g. China, Japan and Korea) have significantly greater risks of EPSs than non east Asian patients, indicating a clear interethnic difference in vulnerability to the development of EPSs [5] . Asian populations have also been found to have slower metabolism rates of certain antipsychotics, leading to an increased prevalence of AEs. Intriguingly, however, the prevalence of tardive dyskinesia (TD) is lower in Asian than western populations [28] , suggesting that Asian MDD patients may have some advantageous for long-term treatment with AAs. These differences are thought to be from differences in the expression of genetic polymorphisms, such as the dopamine D3 receptor gene (DRD3) and DRD2 that are principally related to the development of movement disorders, although some debate still exists [29, 30] . On the other hand, Asian patients were found to have greater susceptibility to developing anticholinergic side effects, blood dyscrasia and metabolic abnormalities, including hypertension, diabetes mellitus and weight gain, from antipsychotic treatment [5, 31, 32] . Therefore, clinicians should consider ethnic differences in pharmacokinetics, particularly with regard to the development of AEs, in prescribing AAs.
To treat EPSs in clinical practice, anticholinergic agents are usually prescribed. What is appropriate in the use of anticholinergic agents? (For example, should they be used as a prophylactic, after EPS, or during the entire treatment?) There are no data supporting a prophylactic use of anticholinergic agents for EPSs, and existing research indicates that anticholinergic agents have questionable long-term benefits and carry the risk of various AEs, including cognitive impairment and worsening of movement disorders [33] . Therefore, the use of anticholinergic agents for MDD patients is recommended to be short term with early discontinuation, particularly for Asians with their greater vulnerability to anticholinergic AEs. In fact, the most common interventions associated with EPS resolution were dose reduction of aripiprazole (51 %) and no intervention (36 %), in registration clinical trials of aripiprazole for MDD [7] .
Health insurance policies to reduce healthcare utilization and expenditures vary substantially across Asian countries (as well as compared with western countries) depending on their national funding resource [34] , and thus Therefore, differences in AE profiles, dose requirements, psychiatric and medical comorbidities, drug interactions, pharmacodynamic differences and approved indications should be considered in the selection of AAs as an augmentation therapy for treating Asian patients with MDD. Recommendations for augmenting antidepressants with AAs for Asian patients with MDD considering different ethnic backgrounds are presented in Table 2 .
Conclusions
As several AAs have demonstrated efficacy as augmentation of antidepressants in patients who fail to show adequate response to initial treatment, the use of AAs has dramatically increased [36] ; however, there is insufficient clinical information to develop clear guidelines for the use of AAs in Asian MDD patients. Although AAs have demonstrated efficacy as augmentation therapy for treating MDD in western populations, studies with Asian populations are limited, and those that exist suggest differences. Further controlled clinical trials, long-term studies, analyses of benefit-risk ratios of currently approved AAs with various antidepressants and studies based on pharmacokinetic variations between Asian and western population are greatly needed. The viability of AAs as a treatment option for Asian patients with MDD should depend on further information regarding Asian-specific pharmacological and clinical factors associated with treatment outcomes and tolerability issues in clinical practice.
